Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
ACADIA Pharmaceuticals has appointed Gudarz Davar to executive vice president and head of research and development. Most recently, Davar was vice president and head of global neurology clinical development at Eli Lilly.
Acepodia has named Mark Gilbert as senior vice president of research and development. Previously, Gilbert was chief medical officer of Juno Therapeutics. Acepodia has also appointed Joseph McCracken, former vice president and global head of business development and licensing for Roche Pharmaceuticals, to the role of senior vice president of business development.
Actimed Therapeutics has appointed Chika Yoshinaga to development, partnering and financing adviser for Japan and China. Yoshinaga was previously head of corporate development in Japan and China for Quintiles Pharmaceuticals (IQVIA).
Netherlands-based Amarna Therapeutics has appointed Steen Klysner as its newest CEO. Klysner comes to the company from a CEO position at ExpreS2ion Biotech.
Association for Accessible Medicines
Dan Leonard, former president and CEO of the National Pharmaceutical Council, has been named president and CEO of the Association for Accessible Medicines.
Fouad Namouni has been appointed to president of R&D at Blueprint Medicines. Namouni most recently served as senior vice president and head of oncology development at Bristol Myers Squibb.
BrainStorm Cell Therapeutics
Anthony Waclawski has been named executive vice president and global head of regulatory affairs at BrainStorm Cell Therapeutics. Waclawski was most recently vice president and head of regulatory and pharmaceutical sciences, cardiovascular, immunosciences, fibrosis and genetically defined diseases at Bristol Myers Squibb.
Doug Drysdale has taken the helm at Cybin as its newest CEO. Most recently, Drysdale was president and CEO of Tedor Pharma.
Michael Curtis has been appointed to president of R&D at eGenesis. Curtis most recently served as president and head of R&D at Cadent Therapeutics.
Ingrid Hoos has been named senior vice president of scientific affairs at Eton Pharmaceuticals. Most recently, Hoos was vice president of regulatory affairs at Horizon Therapeutics.
Galectin Therapeutics has appointed Joel Lewis to CEO. Lewis was recently managing director of shareholder services at Uline.
William Gannon has been named vice president of regulatory affairs at Genprex. Gannon currently serves as chief scientific officer and medical director at Capital City Technical Consulting.
Hoth Therapeutics has named Stefanie Johns as chief scientific officer. Formerly, Johns was director of regulatory affairs at Enable Injections.
Idealliance has announced Michael Grady will now serve as its vice president of global partnerships. Grady was most recently global marketing director at sgsco.
Sven Rohmann has been appointed to CEO of Immunicum. Formerly, Rohmann was acting CEO for Oasmia Pharmaceutical.
Hans Pedersen, current vice president of business development at diagnostics company Immunovia, has assumed the duties of Peter Schultz-Knappe, who has recently stepped down from his role of chief technology officer at the company. Pedersen has also been promoted to vice president of strategy and business development.
LB Pharmaceuticals has hired Anna Eramo to fill its chief medical officer role. Eramo was most recently clinical and medical affairs head at Lundbeck.
Lisa Olson has been named chief scientific officer of Magenta Therapeutics. Formerly, Olson was vice president of immunology discovery and site head at AbbVie Bioresearch Center. Magenta Therapeutics also named Kevin Johnson as senior vice president and head of regulatory and quality. Most recently, Johnson was senior vice president of regulatory affairs, quality and pharmacovigilance at Imara.
Kevin Kaiserman, owner of SoCal Diabetes, has joined MannKind as vice president of medical affairs and safety.
Chuck Miller has been appointed to senior vice president of regulatory affairs at Mersana Therapeutics. Miller was previously vice president of regulatory strategy and labeling at TESARO.
Metacrine has appointed Catherine Lee to senior vice president and general counsel and Theresa Lowry to vice president of human resources. Lee was most recently senior vice president and general counsel at Omnione, and Lowry previously served as head of global human resources operations and total rewards at Arena Pharmaceuticals.
Scott Edmondson has been named senior vice president and head of chemistry at Nimbus Therapeutics. Prior to Nimbus, Edmondson served as director and head of Boston oncology chemistry at AstraZeneca.
Nocion Therapeutics has named Christopher Silber as its chief medical officer. Silber joins Nocion from SAGE Therapeutics, where he served as senior vice president of clinical development.
Biotech company Pictor has named Thomas Schlumpberger as its newest CEO. Schlumpberger was most recently executive vice president of diagnostics at Anixa Biosciences.
Robert Bowdish is PRISYM ID’s new director of clinical trials sales for North America. Bowdish comes to PRISYM from a position as senior director for regulatory clinical solutions, global sales, at Parexel.
Recce Pharmaceuticals has appointed James Graham as CEO. Graham was previously an executive director of the company.
Victor Wroblewski has been named senior vice president and head of biology of Sparx Therapeutics. Previously, Wroblewski was vice president of biotherapeutics development at AIT Bioscience.